| Sembua Samuel Danieli, MD | |
|
501 Morris St, Charleston, WV 25301-1326 | |
| (304) 388-5432 | |
| Not Available |
| Full Name | Sembua Samuel Danieli |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 31 Years |
| Location | 501 Morris St, Charleston, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497789150 | NPI | - | NPPES |
| 010087911 | Medicaid | VA | |
| P00131792 | Other | RAILROAD MEDICARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Unc Lenoir Health Care | Kinston, NC | Hospital |
| Rex Hospital | Raleigh, NC | Hospital |
| Carolina East Medical Center | New bern, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rex Hospital Inc | 0840109864 | 652 |
| Unc Physicians Network | 5496940546 | 709 |
| Cogent Healthcare Of North Carolina Pc | 7911954714 | 123 |
News Archive
A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.
Our public health organizations strongly support the bipartisan legislation introduced today in both the House and Senate to provide the U.S. Food and Drug Administration (FDA) with effective authority to regulate tobacco products.
A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 2 days ago
| Entity Name | Cogent Healthcare Of North Carolina Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548207483 PECOS PAC ID: 7911954714 Enrollment ID: O20050404001057 |
News Archive
A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.
Our public health organizations strongly support the bipartisan legislation introduced today in both the House and Senate to provide the U.S. Food and Drug Administration (FDA) with effective authority to regulate tobacco products.
A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 2 days ago
| Entity Name | Unc Physicians Network Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750704367 PECOS PAC ID: 5496940546 Enrollment ID: O20101115000646 |
News Archive
A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.
Our public health organizations strongly support the bipartisan legislation introduced today in both the House and Senate to provide the U.S. Food and Drug Administration (FDA) with effective authority to regulate tobacco products.
A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 2 days ago
| Entity Name | Rex Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144248683 PECOS PAC ID: 0840109864 Enrollment ID: O20140613001181 |
News Archive
A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.
Our public health organizations strongly support the bipartisan legislation introduced today in both the House and Senate to provide the U.S. Food and Drug Administration (FDA) with effective authority to regulate tobacco products.
A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 2 days ago
| Entity Name | Usacs Integrated Acute Care Services Of North Carolina, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437869302 PECOS PAC ID: 2365813722 Enrollment ID: O20230121000061 |
News Archive
A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.
Our public health organizations strongly support the bipartisan legislation introduced today in both the House and Senate to provide the U.S. Food and Drug Administration (FDA) with effective authority to regulate tobacco products.
A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sembua Samuel Danieli, MD 400 Association Dr Ste 102, Charleston, WV 25311-1298 Ph: () - | Sembua Samuel Danieli, MD 501 Morris St, Charleston, WV 25301-1326 Ph: (304) 388-5432 |
News Archive
A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.
Our public health organizations strongly support the bipartisan legislation introduced today in both the House and Senate to provide the U.S. Food and Drug Administration (FDA) with effective authority to regulate tobacco products.
A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 2 days ago
Dr. Andrew D. Myers, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3200 Maccorkle Ave Se, Robert C. Byrd Clinical Training Center, 4th Floor, Charleston, WV 25304 Phone: 304-388-5590 Fax: 304-388-8238 | |
Mr. Andrei Vladimirovitch Malko, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 3200 Maccorkle Ave Se Ste B-16, Charleston, WV 25304 Phone: 304-388-5848 Fax: 304-388-9654 | |
Dr. Khawaja Owais Omar, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3100 Maccorkle Ave Se Ste 700, Charleston, WV 25304 Phone: 304-720-7305 | |
Dr. Amanda C. Shuff, DO Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 3200 Maccorkle Ave Se, Suite B16, Charleston, WV 25304 Phone: 304-388-5848 Fax: 304-588-9654 | |
Salman Shaukat, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3100 Maccorkle Ave Se Ste B16, Charleston, WV 25304 Phone: 304-388-9612 Fax: 304-388-9654 | |
Mohammad Akram Kawsara, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3200 Maccorkle Ave Se, Suite B16, Charleston, WV 25304 Phone: 304-388-5848 Fax: 304-388-9654 | |
Dr. Cynthia Elizabeth Collins Stump, D.O. Hospitalist Medicare: Medicare Enrolled Practice Location: 3701 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-720-2345 Fax: 304-720-2347 |